You are here

Targeting the sphingolipid pathway for the R&D of new antifungals

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AI134428-01A1
Agency Tracking Number: R41AI134428
Amount: $279,393.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA17-303
Timeline
Solicitation Year: 2017
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-08-01
Award End Date (Contract End Date): 2019-07-31
Small Business Information
86 DEER PARK RD
Dix Hills, NY 11746-4900
United States
DUNS: 080296540
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 MAURIZIO DELPOETA
 (631) 632-4024
 maurizio.delpoeta@stonybrook.edu
Business Contact
 JOHN MCCARTHY
Phone: (917) 833-0043
Email: brian.mccarthy@microrid.com
Research Institution
 RESEARCH FOUNDATION FOR THE STATE UNIVER
 
80 EATON ST
MORRISVILLE, NY 13408-2608
United States

 Domestic Nonprofit Research Organization
Abstract

ABSTRACT
The goal of this project is to discover and develop a new therapeutic smore potent than current antifungals for the
treatment of invasive fungal infectionsAmong invasive fungal infectionscryptococcosiscandidiasisand
aspergillosis are the most life threateningThe incidence of these infections has risen more thanfold over the
lastyearswith a mortality rate ofyearWe recently discovered a fungal enzymeceramide synthaseCeressential for fungal growth at neutralalkaline
and acidic environmentsThusa fungal mutant lacking Ceris not pathogenic in animal models becauseupon
infectionit cannot survive in host neutrallung and other organsalkalinebloodand acidicinflammatory tissueenvironmentsThusCeris an ideal target for the development of new antifungals because any compound blocking Cerwill be
fungicidalWe have optimized a high throughput assay that allows the screen for selective and specific inhibitors of
fungal CerThuswe will screen ChemBridge DIVERSet libraries for compounds inhibiting fungal Cerbut not
human ceramide synthases and select potent hit molecule sto move forward for medicinal chemistry and preclinical
studiesWe do have the experience and expertise to perform these studies NARRATIVE
Fungal infections have dramatically increased during the last decade and new treatment
strategies are neededThis proposal focuses on developing new compounds targeting
the fungal but not the mammalian sphingolipid pathway

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government